Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Myeloid, Chronic-Phase 5Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Myeloproliferative Disorders 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Gastrointestinal Stromal Tumors 1GIST 1

Interventions

Cyclophosphamide 80Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 73Busulfan 53Tacrolimus 50Cyclosporine 48Methotrexate 45Antilymphocyte Serum 45Mycophenolic Acid 43Filgrastim 39Radiotherapy 36Whole-Body Irradiation 35Methylprednisolone 28Melphalan 25Cord Blood Stem Cell Transplantation 24Cytarabine 21Etoposide 20sargramostim 14Thiotepa 13Flow Cytometry 13Imatinib Mesylate 12merphos 11Therapeutics 10Sirolimus 10Rituximab 10Dasatinib 9Psychiatric Rehabilitation 8Transplantation 7Polymerase Chain Reaction 7Carboplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Accelerated Phase × olverembatinib × Clear all
NCT03883100 2023-04-03

A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation

Ascentage Pharma Group Inc.

Phase 2 Unknown
23 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡